- Supported exchanges /
- TWO /
- 6696.TWO
Lin BioScience Inc. (6696 TWO) stock market data APIs
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Lin BioScience Inc. Financial Data Overview
| 96.4 | |
| 92.9 | |
| - | |
| 97.7 | |
| 92.3 | |
| 70-126.5 | |
| 7 580 M | |
| 78 630 K | |
| 0 | |
| -0.1 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Lin BioScience Inc. Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -1 270 548 992
- Earnings Per Share -9.52
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Lin BioScience Inc. Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get Lin BioScience Inc. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
